A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
(2011) In Rheumatology (Oxford, England) 50. p.899-905- Abstract
- Objective. Assessment of disease activity in vasculitis can be achieved using the BVAS, a clinical checklist of relevant symptoms, signs and features of active disease. The aim of this study was to revalidate the BVAS version 3 (BVAS v. 3) in a cohort of patients with systemic vasculitis. Methods. A total of 238 patients with vasculitis from seven countries in Europe were evaluated at a single time point. Spearman's correlation coefficients were calculated between BVAS v. 3 scores, vasculitis activity index (VAI), physician's global assessment (PGA), the physician's treatment decision, CRP and the vasculitis damage index (VDI) to demonstrate that the BVAS v. 3 measures disease activity. Results. WG (63%), Churg-Strauss syndrome (9%) and... (More)
- Objective. Assessment of disease activity in vasculitis can be achieved using the BVAS, a clinical checklist of relevant symptoms, signs and features of active disease. The aim of this study was to revalidate the BVAS version 3 (BVAS v. 3) in a cohort of patients with systemic vasculitis. Methods. A total of 238 patients with vasculitis from seven countries in Europe were evaluated at a single time point. Spearman's correlation coefficients were calculated between BVAS v. 3 scores, vasculitis activity index (VAI), physician's global assessment (PGA), the physician's treatment decision, CRP and the vasculitis damage index (VDI) to demonstrate that the BVAS v. 3 measures disease activity. Results. WG (63%), Churg-Strauss syndrome (9%) and microscopic polyangiitis (9%) were the most common diagnoses. The BVAS v. 3 showed convergent validity with the VAI [ρ = 0.82 (95% CI 0.77, 0.85)], PGA [ρ = 0.85 (95% CI 0.81, 0.88)] and the physician's treatment decision [ρ = 0.54 (95% CI 0.44, 0.62)]. There was little or no correlation between BVAS v. 3 and the CRP level [ρ = 0.18 (95% CI 0.05, 0.30)] or with the VDI [ρ = -0.10 (95% CI 0.22, 0.03)]. The inter-observer reliability was very high with an intra-class correlation coefficient (ICC) of 0.996 (95% CI 0.990, 0.998) for the total BVAS v. 3 score. Conclusion. The BVAS v. 3 has been evaluated in a large cohort of patients with vasculitis and the important properties of the tool revalidated. This study increases the utility of the BVAS v. 3 in different populations of patients with systemic vasculitis. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1756400
- author
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Rheumatology (Oxford, England)
- volume
- 50
- pages
- 899 - 905
- publisher
- Oxford University Press
- external identifiers
-
- wos:000289840300013
- pmid:21156667
- scopus:79955141104
- pmid:21156667
- ISSN
- 1462-0332
- DOI
- 10.1093/rheumatology/keq400
- language
- English
- LU publication?
- yes
- id
- 6e2a445e-d48f-4e8a-a352-5258290d9595 (old id 1756400)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21156667?dopt=Abstract
- date added to LUP
- 2016-04-04 09:16:42
- date last changed
- 2022-04-23 19:51:45
@article{6e2a445e-d48f-4e8a-a352-5258290d9595, abstract = {{Objective. Assessment of disease activity in vasculitis can be achieved using the BVAS, a clinical checklist of relevant symptoms, signs and features of active disease. The aim of this study was to revalidate the BVAS version 3 (BVAS v. 3) in a cohort of patients with systemic vasculitis. Methods. A total of 238 patients with vasculitis from seven countries in Europe were evaluated at a single time point. Spearman's correlation coefficients were calculated between BVAS v. 3 scores, vasculitis activity index (VAI), physician's global assessment (PGA), the physician's treatment decision, CRP and the vasculitis damage index (VDI) to demonstrate that the BVAS v. 3 measures disease activity. Results. WG (63%), Churg-Strauss syndrome (9%) and microscopic polyangiitis (9%) were the most common diagnoses. The BVAS v. 3 showed convergent validity with the VAI [ρ = 0.82 (95% CI 0.77, 0.85)], PGA [ρ = 0.85 (95% CI 0.81, 0.88)] and the physician's treatment decision [ρ = 0.54 (95% CI 0.44, 0.62)]. There was little or no correlation between BVAS v. 3 and the CRP level [ρ = 0.18 (95% CI 0.05, 0.30)] or with the VDI [ρ = -0.10 (95% CI 0.22, 0.03)]. The inter-observer reliability was very high with an intra-class correlation coefficient (ICC) of 0.996 (95% CI 0.990, 0.998) for the total BVAS v. 3 score. Conclusion. The BVAS v. 3 has been evaluated in a large cohort of patients with vasculitis and the important properties of the tool revalidated. This study increases the utility of the BVAS v. 3 in different populations of patients with systemic vasculitis.}}, author = {{Suppiah, Ravi and Mukhtyar, Chetan and Flossmann, Oliver and Alberici, Federico and Baslund, Bo and Batra, Rajbir and Brown, Denise and Holle, Julia and Hruskova, Zdenka and Jayne, David R W and Judge, Andrew and Little, Mark A and Palmisano, Alessandra and Stegeman, Coen and Tesar, Vladimir and Vaglio, Augusto and Westman, Kerstin and Luqmani, Raashid}}, issn = {{1462-0332}}, language = {{eng}}, pages = {{899--905}}, publisher = {{Oxford University Press}}, series = {{Rheumatology (Oxford, England)}}, title = {{A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.}}, url = {{http://dx.doi.org/10.1093/rheumatology/keq400}}, doi = {{10.1093/rheumatology/keq400}}, volume = {{50}}, year = {{2011}}, }